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Lipid biosynthesis is essential for the maintenance of
cellular homeostasis. The lipidsproducedbycells (glycero-
lipids, fatty acids, phospholipids, cholesterol, andsphingo-
lipids) are used as an energy source/reserve, as building
blocks for membrane biosynthesis, as precursor mole-
cules for the synthesis of various cellular products, and
as signaling molecules. Defects in lipid synthesis or pro-
cessing contribute to the development of many diseases,
including obesity, insulin resistance, type 2 diabetes,
non-alcoholic fatty liver disease, and cancer. Studies pub-
lished over the last few years have shown that the target of
rapamycin (TOR), aconservedserine/threoninekinasewith
an important role in regulating cell growth, controls lipid
biosynthesis through various mechanisms. Here, we
review these findings and briefly discuss their potential
relevance for human health and disease.
Introduction
The mammalian TOR (mTOR) protein is a serine/threonine
kinase belonging to the phosphoinositide 3-kinase (PI3K)-
related kinase family that has an important role in regulating
cell growth and metabolism. As depicted in Figure 1, mTOR
nucleates at least two distinct multi-protein complexes:
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)
(reviewed in [1]). mTORC1 is composed of mTOR, regulatory-
associated protein of mTOR (Raptor), mammalian lethal with
Sec13 protein 8 (mLST8, also known as GbL), proline-rich
Akt substrate 40kDa (PRAS40), and DEP-domain-containing
mTOR-interacting protein (Deptor). This complex integrates
four major signals — growth factors, energy status, oxygen,
and amino acids — to regulate many processes involved in
the control of cell growth and metabolism. mTORC2, which
is composed of mTOR, rapamycin-insensitive companion
of mTOR (Rictor), mammalian stress-activated protein kinase
interacting protein (mSin1), protein observed with Rictor-1
(Protor-1), mLST8, and Deptor, is activated by growth factors
and regulates cell survival, cell metabolism, and cytoskeletal
organization (reviewed in [2]).
From yeast to mammals, favorable conditions, such as
nutrient and oxygen availability, induce cell growth by acti-
vating the TOR pathway. For many years, regulation of cell
growth by mTOR has been studied mostly in relation to
protein synthesis, the best-characterized biological output
controlled by this pathway. However, it is becoming increas-
ingly clear that mTOR also controls cell growth by promoting
the activation of other anabolic processes, leading to the
1Whitehead Institute for Biomedical Research, Nine Cambridge
Center, Cambridge, MA 02142, USA. 2Howard Hughes Medical
Institute, Department of Biology, Massachusetts Institute of
Technology, Cambridge, MA 02139, USA. 3Koch Center for
Integrative Cancer Research at MIT, 77 Massachusetts Avenue,
Cambridge, MA 02139, USA.
*E-mail: sabatini@wi.mit.edusynthesis of many classes of lipids (unsaturated and satu-
rated fatty acids, phosphatidylcholine, phosphatidylgly-
cerol, and sphingolipids) that are required for membrane
biosynthesis and energy storage. Here, we review these find-
ings, focusing on what has been learnt about mTORC1 effec-
tors in lipid synthesis and about a possible role for mTORC2
in lipogenesis from studies of lower organisms. We also
discuss the potential relevance of these recent findings for
the treatment of human diseases, including cancer, obesity,
and non-alcoholic fatty liver disease (NAFLD).
mTORC1-Mediated Control of Lipogenesis
through SREBP-1
When total energy intakeexceeds energyexpenditure, excess
carbohydrates are converted to fatty acids and deposited for
storage as triglycerides in hepatic and adipose tissue. This
process, defined as de novo lipogenesis, is strongly driven by
insulin (reviewed in [3]). The binding of insulin to its cell surface
receptor activates PI3K, promotes the production of phos-
phatidylinositol (3,4,5)-triphosphate (PIP3), and increases the
recruitment and the activation of Akt at the plasma membrane
(reviewed in [4]). When activated, Akt positively regulates
denovo lipogenesis by promoting glucose uptake, glycolysis,
and the expression of genes involved in lipid biosynthesis
(reviewed in [5]). Many lines of evidence suggest that Akt
mediates the effect of insulin on de novo lipogenesis by acti-
vating the transcription factor sterol regulatory element-
binding protein-1 (SREBP-1) (reviewed in [6]).
SREBPs are basic helix–loop–helix transcription factors
that regulate lipid homeostasis by controlling the expression
of genes required for cholesterol, fatty acid, triglyceride, and
phospholipid synthesis. Three members of the SREBP family
have been described in mammals: SREBP-1a and -1c, which
are produced by alternative splicing; and SREBP-2, which is
encoded by another gene. SREBP-1c and -2 are considered
the most physiologically relevant because of their high
expression in lipogenic tissues (reviewed in [7]). SREBPs
are synthesized in the endoplasmic reticulum (ER) in the
form of a precursor protein. In order to reach the nucleus
and act as a transcription factor, the amino-terminal domain
of each SREBP must be released from the ER proteolytically.
SREBP-1 and -2 are cleaved and activated in response to
different signals: SREBP-2 is activated in response to
cellular sterol depletion, whereas SREBP-1c, which is insen-
sitive to sterol levels, is activated by insulin (reviewed in [7]).
Accordingly, studies using genetically engineered mouse
models show that SREBP-2 mainly controls cholesterol
biosynthesis, whereas SREBP-1c is involved in insulin-medi-
ated fatty acid synthesis (reviewed in [6]).
Insulin treatment or constitutive Akt activation rapidly
induces nuclear accumulation of SREBP-1 and the expres-
sion of lipogenic genes [8,9]. The precise mechanism by
which insulin signaling promotes SREBP-1 cleavage has
remained elusive for many years. As shown in Figures 1
and 2, growth factors such as insulin increase Akt activity,
which in turn promotes mTORC1 activation by directly phos-
phorylating tuberous sclerosis complex 1/2 (TSC1/2) and
PRAS40. Porstmann et al. [10] observed that inhibition of
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Figure 1. Overview of the mTOR signaling
pathway.
The mTOR kinase nucleates two characterized
protein complexes termed mTORC1 and
mTORC2. mTORC1 is composed of five
subunits: the mTOR catalytic subunit, Raptor,
mLST8, PRAS40, and Deptor. The mTORC2
complex contains six proteins: mTOR, Rictor,
mSin1, Protor-1, mLST8, and Deptor. mTORC1
is sensitive to nutrients and is inhibited by
FKBP12-rapamycin. One of the most impor-
tant sensors involved in the regulation of
mTORC1 activity is TSC, which is a hetero-
dimer composed of TSC1 and TSC2. TSC1/2
functions as a GTPase-activating protein for
the small, Ras-related GTPase, Rheb. The
active, GTP-bound form of Rheb directly inter-
acts with mTORC1 to stimulate its activity. As
a Rheb-specific GAP, TSC1/2 negatively regu-
lates mTORC1 signaling by converting Rheb
into its inactive GDP-bound state. Stimulation
of cells with growth factors activates Akt,
extracellular signal-regulated kinase (Erk),
and ribosomal S6 kinase (Rsk), which inacti-
vates TSC and promotes Rheb activation. Akt
activation also promotes mTORC1 activity by
phosphorylating PRAS40, a negative regulator
of mTORC1. Induction of Redd1 and AMPK by
hypoxia and energy deficit activates TSC1/2 and downregulates mTORC1 signaling. The activation of mTORC1 by amino acids is regulated by the
Rag GTPase and is independent of TSC1/2. Activation of mTORC1 by growth factors or amino acids promotes protein synthesis via the phosphor-
ylation of S6K1 and 4E-BPs. High activation of S6K1 by mTORC1 induces a feedback inhibition loop in which S6K1 reduces growth factor signaling
by promoting the phosphorylation and the degradation of IRS-1. mTORC2 is activated by growth factors and regulates many AGC kinases (Akt,
SGK1, protein kinase C (PKC) a) that have key roles in controlling cell survival, metabolism and cytoskeletal organization. This complex is insen-
sitive to FKBP12–rapamycin but is inhibited by the newly characterized mTOR inhibitor Torin1. FKBP12, intracellular receptor for rapamycin; IRS-1,
insulin receptor substrate-1; Redd1, transcriptional regulation of DNA damage response-1; Rheb, Ras homolog enriched in brain.mTORC1 with rapamycin blocks Akt-induced SREBP-1
nuclear localization, the expression of lipogenic genes, and
the production of various classes of lipids (unsaturated and
saturated fatty acids, phosphatidylcholine, and phosphatidyl-
glycerol). The knockdown of Raptor, but not Rictor, showed
similar effects, indicating that SREBP-1 activation by Akt
depends on mTORC1 but not mTORC2. This finding supports
previous work that showed that rapamycin reduces the
expression of many SREBP-1 target genes, including acetyl-
CoA carboxylase (ACC) [11], fatty acid synthase (FASN) [12],
and stearoyl-CoA desaturase 1 (SCD-1) [13]. In addition to
establishing a link between mTORC1 and SREBP-1, Porst-
mann et al. [10] nicely demonstrated that SREBP-1 depletion
restricts mammalian cell growth and fly size, suggesting that
the PI3K–Akt–TORC1 pathway regulates cell size by pro-
moting both protein and lipid biosynthesis. The exact mecha-
nism by which mTORC1 promotes SREBP-1 cleavage and
nuclear localization remains to be determined.
Increased de novo lipid synthesis is a hallmark of prolifer-
ating cancer cells (reviewed in [14]). Uncontrolled growth
factor signaling caused by the mutation/amplification of
genes encoding proteins involved in PI3K and Ras signaling
is commonly observed in tumors and serves as a key
signaling event leading to the activation of SREBP-1 and
de novo lipogenesis (Figure 2). A significant body of evidence
suggests that the induction of lipid biosynthesis through
the activation of SREBP-1 facilitates cancer progression
by providing the lipids required for membrane synthesis
(reviewed in [14]). The observation that mTORC1 promotes
SREBP-1 activation indicates that this protein complex
may play a central role in cancer cell growth/proliferation
by relaying growth factor signals to lipid synthesis (Figure 2).These results strongly suggest that mTORC1 inhibition with
rapamycin, or with the newly characterized mTOR inhibitors
[15–17], may reduce cancer cell growth/proliferation by
blocking both protein and lipid biosynthesis. Further investi-
gations are needed to support this hypothesis.
NAFLD, a condition produced by fat accumulation in the
liver, is the most common liver disease and can eventually
lead to non-alcoholic steatohepatitis, cirrhosis and hepato-
cellular carcinomas (reviewed in [18]). NAFLD is commonly
observed in obese subjects and is closely linked to insulin
resistance and metabolic syndrome, a combination of
medical disorders that increase the risk of developing
cardiovascular diseases and type 2 diabetes. A recent study
performed in obese humans revealed an important role
of de novo lipogenesis in the excessive accumulation of
hepatic triglycerides [19]. Although highly dependent on
insulin for its activation, lipogenesis is paradoxically very
active in the liver of obese rodents, which are characterized
by severe hepatic insulin resistance. Interestingly, mTORC1
is also highly active in the liver of obese rodents [20]. In addi-
tion to reducing insulin signaling by promoting insulin
receptor substrate-1 (IRS-1) phosphorylation or degradation
(Figure 1), mTORC1 hyperactivation by overfeeding may
promote lipogenesis by inducing SREBP-1c cleavage and
activation. The nutrient-dependent activation of mTORC1
may explain why hepatic SREBP-1c is highly activated even
in the context of profound liver insulin resistance. Addition-
ally, it is interesting to note that metformin, an antidiabetic
drug known to activate AMP-activated protein kinase
(AMPK), reduces hepatic lipid content by promoting fatty
acid oxidation and by impairing SREBP-1c expression and
cleavage [21]. Because AMPK negatively regulates mTORC1
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Figure 2. mTORC1 promotes de novo lipogenesis through the activation of SREBP-1.
The activation of mTORC1 in response to growth factors induces many anabolic processes that favor cell growth and proliferation. In addition to
promoting protein synthesis through the phosphorylation of S6K1 and 4E-BPs, mTORC1 controls de novo lipid synthesis by regulating the acti-
vation state of SREBP-1. In detail, growth factors activate Akt, Erk and Rsk, which induce TSC1/2 phosphorylation and lead to mTORC1 activa-
tion. Akt also directly promotes mTORC1 action through the phosphorylation of PRAS40. When activated, mTORC1 favors the cleavage of
SREBP-1 by a mechanism that remains to be established. The cleaved form of SREBP-1 then translocates to the nucleus where it induces the
expression of many lipogenic genes, including acetyl-CoA carboxylase (ACC), acyl-CoA lyase (ACLY), fatty acid synthase (FASN), glycerol-3-
phosphate acyltransferase (GPAT), glucokinase (GK) and stearoyl-CoA desaturase-1 (SCD-1). These proteins catalyze numerous enzymatic
processes that are essential for the synthesis of fatty acids, triglycerides, and phospholipids. Mutations in tumor suppressors or oncogenes
that lead to the overactivation of Ras and insulin signaling pathways are commonly observed in cancer and are thought to promote cell growth
and proliferation by inducing many anabolic processes, including lipid biosynthesis. The induction of lipogenesis through the activation of
SREBP-1 promotes cancer progression by providing the lipids required for membrane synthesis. The fact that mTORC1 promotes SREBP-1 acti-
vation indicates that this protein complex may play a central role in cancer cell growth/proliferation by relaying growth factor signals to lipid
synthesis. FA, fatty acid; Grb2, growth factor receptor bound protein 2; NF-1, neurofibromatosis type 1; PDK1, phosphoinositide-dependent
kinase 1; PTEN, phosphatase and tensin homologue deleted on chromosome 10; SOS, son of sevenless; nSREBP-1, nuclear form of sterol regu-
latory element-binding protein-1; TCA cycle, tricarboxylic acid cycle.(Figures 1 and 2), this suggests that AMPK activators (met-
formin, adiponectin) may reduce fat deposition in the liver
by affecting the expression of lipogenic genes through an
mTORC1–SREBP-1c-dependent mechanism. The involve-
ment of the mTORC1–SREBP-1c axis for the control of lipid
synthesis in the other important lipogenic tissue, i.e. adipose
tissue, will be discussed in the next section.
mTORC1-Mediated Control of Lipogenesis
through PPAR-g and Lipin1
Adipogenesis is the biological process leading to the forma-
tion of mature adipocytes from adipose cell precursors. This
process follows a well-orchestrated program in whichCCAAT/enhancer binding protein-b (C/EBP-b) and C/EBP-d
trigger the expression of C/EBP-a, which in turn induces the
expression of peroxisome proliferator-activated receptor-g
(PPAR-g), a member of the nuclear receptor superfamily of
ligand-activated transcription factors (reviewed in [22]). The
activation of PPAR-g leads to profound changes in gene
expression that ultimately lead to the stimulation of fatty acid
uptake, synthesis, esterification, and storage in the newly
formed adipose cell.
Rapamycin strongly inhibits the adipogenic program in
mouse and human pre-adipocytes in vitro [23–29]. It was
initially shown that rapamycin blocks adipogenesis by
impairing the clonal expansion of pre-adipocytes [29], an
Review
R1049early event thought to be required for the establishment of
the normal adipogenic program in vitro (reviewed in [22]).
Over the following years, it was found that rapamycin
severely reduces lipid accumulation in fat cells even when
added after clonal expansion, indicating that mTORC1
affects adipogenesis and adipocyte maintenance through
additional mechanisms [23,24,26,28]. Most of the studies
linking mTOR signaling to adipogenesis were based on
long-term rapamycin treatments, an experimental condition
that can also lead to mTORC2 inhibition [30]. To determine
the specific role of mTORC1 in adipogenesis and adipocyte
maintenance, Polak et al. [28] knocked down Raptor in
3T3-L1 adipocytes and observed a reduction in adipogene-
sis. Additionally, it was recently shown that adipose-specific
deletion of Rictor does not affect adipocyte size and adipose
tissue mass in vivo [31]. Although it remains to be determined
if acute knockdown of Rictor leads to similar effects, these
observations strongly suggest that mTORC1, but not
mTORC2, plays a key role in adipogenesis in mammalian
cells.
Although the exact mechanism linking mTORC1 signaling
to adipogenesis and adipocyte maintenance is unknown,
observations suggest that mTORC1 may control these
processes by regulating the expression and the activation
state of PPAR-g (Figure 3). Many independent groups have
reported that rapamycin-mediated mTOR inhibition reduces
mRNA and protein levels of PPAR-g and C/EBP-a and the
expression of numerous lipogenic genes in vitro [23,24,26].
Accordingly, constitutive activation of mTORC1 via loss of
TSC2 increases PPAR-g and C/EBP-a expression and
promotes adipogenesis [32]. Some evidence indicates that
eukaryotic initiation factor 4E-binding proteins 1 and 2
(4E-BP1 and 2), negative regulators of translation that are
inhibited by mTORC1, are important for the regulation of
PPAR-g and C/EBPs by mTORC1 [27,33]. Disruption of 4E-
BP1/2 promotes the expression of PPAR-g, C/EBP-a, and
C/EBP-d and increases adipogenesis/lipid synthesis in
mouse embryonic fibroblasts [33]. Although the activation
of p70 ribosomal S6 kinase 1 (S6K1), and probably other
mTORC1 substrates, is induced by the deletion of 4E-BP1/2
[33], these results suggest that mTORC1 controls adipo-
genesis/lipogenesis by inducing the translation of mRNA
encoding key components of the adipogenic program,
namely PPAR-g and C/EBP-a. Additionally, the observation
that S6K1-deficient mice have reduced adipose tissue mass
and are protected against diet-induced obesity indicates
that mTORC1 may also control adipogenesis/lipogenesis
through this effector [34]. The molecular mechanism by
which S6K1 may control lipid metabolism is unknown.
It is interesting to note that mTORC1 may also regulate adi-
pogenesis through additional and complementary mecha-
nisms. As discussed in the previous section, mTORC1 pro-
motes lipid synthesis by increasing SREBP-1 cleavage and
activation [10]. SREBP-1 activation triggers the production
of endogenous ligands for PPAR-g and this promotes the
transactivation activity of this nuclear receptor [35]. Interest-
ingly, Kim et al. [24] observed that the synthetic PPAR-g
ligand troglitazone can overcome the inhibitory effect of
rapamycin on adipogenesis, suggesting that mTORC1 inhi-
bition may block adipogenesis by reducing the production of
endogenous PPAR-g ligands. However, it is possible that
troglitazone, as an unnatural ligand, may override the normal
requirements for PPAR-g activation and thus counter rapa-
mycin inhibition unspecifically. The fact that conditionedmedia obtained from normally differentiated adipocytes
cannot correct the adipogenic defect of adipocytes treated
with rapamycin indicates that this possibility may be true
[24]. Additional work is needed to clarify this point.
Lipin1 is a phosphatidic acid phosphatase that promotes
triglyceride synthesis by converting phosphatidic acid to
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Figure 3. mTORC1 promotes adipogenesis and adipocyte mainte-
nance through various mechanisms.
Much evidence indicates that mTORC1 controls adipogenesis by acti-
vating PPAR-g, a nuclear receptor controlling the expression of
numerous genes involved in fatty acid uptake, synthesis, esterification,
and storage. Many mechanisms are thought to be involved in the regu-
lation of PPAR-g by mTORC1. Activation of mTORC1 induces the
phosphorylation of 4E-BPs, which in turn releases eIF4E and increases
the translation of C/EBP-a and -d, which are key components required
for the establishment of the adipogenic cascade. C/EBP-d is known to
drive the expression of C/EBP-a and PPAR-g and to trigger the activa-
tion of a feed-forward loop in which these two transcription factors
reciprocally induce their expression. When sufficient levels of PPAR-g
proteins are produced, this transcription factor promotes adipogene-
sis and lipid synthesis by inducing the expression of many lipogenic
genes. SREBP-1 cleavage by mTORC1 may also contribute to the
induction of adipogenesis by directly favoring triglyceride synthesis
and by promoting the production of endogenous ligands for PPAR-g.
More work is required to determine whether SREBP-1-dependent
production of PPAR-g ligands plays a significant role in the activation
of PPAR-g by mTORC1. Lipin1, a phosphatidic acid phosphatase, was
shown to play a key role in adipogenesis by promoting triglyceride
synthesis and by serving as a coactivator for PPAR-g. Lipin1 is phos-
phorylated in response to insulin and amino acids in a rapamycin-
sensitive fashion. Because rapamycin can inhibit mTORC2 activity in
some cell types, it is unclear whether lipin1 is a direct substrate of
mTORC1 or mTORC2. The biological significance of mTOR-mediated
lipin1 phosphorylation remains to be characterized.
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odystrophy, whereas lipin1 overexpression causes obesity
(reviewed in [36]). In addition to directly promoting triglyc-
eride synthesis through its phosphatidic acid phosphatase
activity, lipin1 acts as a transcriptional coactivator for
many transcription factors, including PPAR-g. Lipin1 physi-
cally interacts with PPAR-g to induce the expression of
many genes playing key roles in adipogenesis [37]. Accord-
ingly, studies with lipin1-null embryonic fibroblasts revealed
that lipin1 is required for the expression of key adipogenic
markers, such as PPAR-g and C/EBP-a, and for the attain-
ment of mature adipocyte functions, including lipogenesis
and lipid accumulation [38]. As a consequence, lipin1 is
though to affect adipogenesis and adipocyte maintenance
by directly promoting triglyceride synthesis and amplifying
the transcriptional activity of PPAR-g. Lipin1 activity is regu-
lated by many mechanisms, including phosphorylation. In
adipocytes, lipin1 is phosphorylated in response to insulin
and amino acids in a rapamycin-sensitive fashion, thus sug-
gesting that mTOR signaling may directly regulate adipogen-
esis/lipogenesis through the control of lipin1 activity [39].
More work is needed to characterize the biological link
between mTOR and lipin1, because the exact consequences
of lipin1 phosphorylation on lipid synthesis and gene expres-
sion have not been characterized so far.
As described throughout this section, the link between
mTORC1 and PPAR-g in the control of adipogenesis and
adipocyte maintenance has been well established in vitro.
In order to determine the role of mTORC1 in adipocytes
in vivo, Polak et al. [28] specifically ablated Raptor in adipose
tissue after the critical steps required for the induction of adi-
pogenesis, thereby focusing on the role of mTORC1 in adipo-
cyte maintenance. In line with the in vitro studies, Raptor
deletion in fat results in lean mice with a reduction in adipo-
cyte size and number. Unexpectedly, the expression of many
genes involved in lipid production and storage, including
PPAR-g and C/EBP-a, is not reduced in adipose tissue of
these animals. Polak et al. [28] observed that mTORC1 inac-
tivation reduces fat accumulation in adipose tissue by
promoting energy expenditure through an induction of
uncoupled respiration. Interestingly, a similar increase in
energy expenditure is observed in many animal models defi-
cient for proteins that play key roles in lipogenesis [40–42].
This raises the possibility that the reduction in fat mass
and the induction of energy expenditure in adipose-specific
Raptor-null animals could be linked to a defect in lipogenesis
that is likely independent of PPAR-g-induced lipogenic gene
expression. The potential implication of lipin1 or SREBP-1 in
this effect has to be considered.
Obesity, defined as an excess amount of body fat relative
to lean body mass, is a major health concern in the United
States and an increasing problem in the developing world.
Recent advances regarding the biology of adipose tissue
have demonstrated that the white adipose tissue plays
a central role in the control of energy balance and acts as
a powerful endocrine organ that mediates numerous physio-
logical and pathological processes (reviewed in [43]). It was
observed that mTORC1 is highly active in the adipose tissue
of obese rodents [34]. The existence of a link between
mTORC1 activation and adipogenesis/lipogenesis suggests
that mTORC1 may play a significant role in the accumulation
of fat when energy intake exceeds energy expenditure.
Understanding the role of mTORC1 signaling in the develop-
ment and the maintenance of adipose tissue and in thecontrol of its endocrine function may promote the devel-
opment of new pharmacological tools to treat metabolic
diseases associated with obesity, such as insulin resistance,
type 2 diabetes and coronary vascular diseases.
Implication of mTORC2 in Lipid Biosynthesis
Two recent reports indicate that impairment of TORC2 func-
tion affects fat accumulation in Caenorhabditis elegans
[44,45]. Despite developmental delay and reduced body
size, Rictor-null worms show increased body fat accumula-
tion, thus suggesting that TORC2 functions as a negative
regulator of lipid deposition in this model. Jones et al. [44]
found that the induction of lipid storage in Rictor-null C. ele-
gans depends on the TORC2 substrate serum- and gluco-
corticoid-induced protein kinase 1 (SGK1) but not Akt, as
only SGK1 loss can mimic the metabolic phenotype associ-
ated with Rictor deletion. The precise mechanism linking the
TORC2–SGK1 axis to lipid metabolism was not described in
this study. In the other report, Soukas et al. [45] observed
that the high-fat phenotype associated with Rictor loss is
associated with a reduction in oxygen consumption and is
dependent on SGK1, but also Akt1 and Akt2. Soukas et al.
also show that the site of action of Rictor in the regulation
of fat mass is the intestine, which is the key site for fat
storage in C. elegans. Although the conclusions drawn in
these reports do not perfectly match, these studies demon-
strate that TORC2 plays a significant role in regulating fat
accumulation in C. elegans and that SGK1 is required in
this process. An interesting question arising from these
observations is whether or not a similar link between
mTORC2 and lipid synthesis exists in mammalian cells.
The fact that adipose-specific Rictor-null mice [31] and
mice lacking SGK isoforms throughout all tissues (reviewed
in [46]) do not show any defect in lipid metabolism suggests
that mTORC2 may have a more subtle role to play in the
control of lipid metabolism in mammals. Whether or not
this is a consequence of the higher genetic redundancy of
mammalian systems remains to be determined.
Although the implication of mTORC2 in the control of lipo-
genesis/adipogenesis appears to be limited in mammals,
recent observations in yeast suggest that this complex
may regulate other facets of lipid metabolism. Aranova
et al. [47] recently showed that the synthesis of minor and
major ceramide species is impaired in yeast cells deficient
in TORC2 activity. In the same report, it was observed that
TORC2 controls de novo sphingolipid synthesis by regu-
lating the activity of ceramide synthase through a mechanism
dependent on Ypk2, the yeast homologue of SGK1. Although
the exact mechanism linking Ypk2 to ceramide synthase has
not been characterized, these results indicate that TORC2
plays a role in transmitting growth signals to sphingolipid
synthesis in yeast. Because the early steps in de novo sphin-
golipid synthesis are well conserved throughout evolution
(reviewed in [48]), it is reasonable to believe that mTORC2
could control this pathway in mammals. Sphingolipids,
which include sphingosine and ceramides, have been impli-
cated in a variety of physiological functions, including differ-
entiation, cell migration and adhesion, cell growth arrest,
senescence and apoptosis. These lipids are believed to
play important roles in many pathological settings, such as
cancer, heart disease, diabetes, microbial infection, neuro-
logical disorders and immune dysfunctions. The possible
implication of mTORC2 in the regulation of ceramide levels
indicates that mTORC2 may play important and yet
Review
R1051undefined roles in these diseases and may also represent
an interesting target for the development of new therapeutic
avenues. Additional studies are required to determine
whether mTORC2 plays a significant role in controlling de
novo sphingolipid synthesis in mammalian cells.
Concluding Remarks
Lipid biosynthesis is essential for the maintenance of cellular
homeostasis and defects in lipid synthesis or processing
contribute to the development of many diseases, including
obesity, insulin resistance, type 2 diabetes, NAFLD, and
cancer. Over the last decade, many groups have shown
that mTOR signaling regulates lipid synthesis through
various effectors, suggesting that this pathway could be tar-
geted for the development of new therapeutic tools for the
treatment of many diseases. Despite outstanding advances,
our understanding of the mechanisms by which mTOR
signaling affects lipid synthesis in mammals is incomplete
and important questions remain to be answered. For
example, how does mTORC1 promote SREBP-1 cleavage
and nuclear localization? What is the exact mechanism by
which mTORC1 regulates the activity of PPAR-g? How
does mTORC1 control lipid synthesis in adipose tissue
in vivo? What is the biological function associated with
lipin1 phosphorylation by mTOR? What is the exact role of
mTORC2 in the regulation of lipogenesis? Does mTORC2
regulate sphingolipid synthesis in mammals? Finding
answers to these questions will improve our understanding
of cell biology and may help to improve the way we treat
many diseases.
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